Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | BHMT | Q93088 | 1/20 | 0.44 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.44 |
| ▸ | GGT1 | P19440 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8015716 | 1.00 | SLC7A5 (0.58) | SLC7A5GABRR1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL199134 | 1.00 | SLC7A5 (0.58) | SLC7A5GABRR1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL2420111 | 1.00 | SLC7A5 (0.58) | SLC7A5GABRR1SLC1A2SLC1A1SLC1A3 | |
| Phosphoric Acid SCHEMBL30009251 | 0.92 | SLC7A5 (0.50) | SLC7A5GABRR1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL18229129 | 0.83 | SLC1A2 (0.64) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL839403 | 0.83 | SLC1A2 (0.64) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL3383446 | 0.83 | SLC1A2 (0.64) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL18229136 | 0.83 | SLC1A2 (0.64) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL2422005 | 0.82 | SLC7A5 (0.62) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL8015345 | 0.82 | SLC7A5 (0.62) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499343-A4 | A METHOD OF MODULATING CELLULAR ACTIVITY | MEDVET SCIENCE PTY LTD (AU) | 2005-12-28 | — | — | EP | disclosed |
| EP-1402032-A4 | BCL-2-MODIFYING FACTOR (BMF) SEQUENCES AND THEIR USE IN MODULATING APOPTOSIS | INST MEDICAL W & E HALL (AU) | 2005-09-07 | — | — | EP | disclosed |
| EP-1499343-A1 | A METHOD OF MODULATING CELLULAR ACTIVITY | MEDVET SCIENCE PTY. LTD. (AU) | 2005-01-26 | — | — | EP | disclosed |
| EP-1402032-A1 | BCL-2-MODIFYING FACTOR (BMF) SEQUENCES AND THEIR USE IN MODULATING APOPTOSIS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-03-31 | — | — | EP | disclosed |
| WO-2004007417-A1 | ENZYME INHIBITORS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003082322-A1 | A METHOD OF MODULATING CELLULAR ACTIVITY | MEDVET SCIENCE PTY. LTD. (AU) | 2003-10-09 | — | — | WO | disclosed |
| WO-2002097094-A1 | BCL-2-MODIFYING FACTOR (BMF) SEQUENCES AND THEIR USE IN MODULATING APOPTOSIS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2002-12-05 | — | — | WO | disclosed |